Kolexia
Bertaut Aurelie Santé publique
Bertaut Aurelie
Santé publique
Centre Georges-François Leclerc
Dijon, France
172 Activités
448 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs colorectales Tumeurs de la prostate Tumeurs du poumon Récidive tumorale locale Métastase tumorale Tumeurs du sein triple-négatives Adénocarcinome Carcinome pulmonaire à petites cellules

Collaborateurs

Voir plus
Ghiringhelli Francois
Ghiringhelli Francois
Centre Georges-François Leclerc, Dijon, France
Desmoulins Isabelle
Desmoulins Isabelle
Centre Georges-François Leclerc, Dijon, France
Crehange Gilles
Crehange Gilles
Clcc Institut Curie, Paris, France
Blanc Julie
Blanc Julie
Hospices civiles de Beaune, Beaune, France

Industries

Voir plus
GE Healthcare
1 collaboration(s)
Dernière en 2022
Pfizer
1 collaboration(s)
Dernière en 2022
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I/II trial.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology   24 février 2024
GUIDE2REPAIR: Precision Medicine Phase II Study Evaluating the Efficacy of a Double Immunotherapy by Durvalumab and Tremelimumab Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes Mutation in Response or Stable After Olaparib Treatment
Essai Clinique (AstraZeneca)   12 février 2024
Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research.
International journal of environmental research and public health   07 février 2024
Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.
Frontiers in oncology   10 janvier 2024
Response to Sorscher.
Journal of the National Cancer Institute   11 novembre 2023
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
BMC cancer   09 novembre 2023
PREDIGOSTEO: Osteopathy and Prevention of Gastrointestinal Side Effects of the Adjuvant Treatment FEC in Women Treated in Day Hospital for Breast Cancer
Essai Clinique (Centre Georges-François Leclerc)   16 octobre 2023
IMMUNOs-SBRT: An Open-label, Multi-centric, Phase I, Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)
Essai Clinique (Centre Georges-François Leclerc)   16 octobre 2023
255P Prognostic stratification capacity of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
346P Quality of life (QoL) and toxicity in patients (pts) with hormone receptor-positive, HER2-negative early breast cancer (HR+, HER2– eBC) treated with adjuvant (adj) endocrine therapy (ET) in the CANcer TOxicities (CANTO) study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023